Actively Recruiting
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
Led by AstraZeneca · Updated on 2026-05-13
450
Participants Needed
6
Research Sites
209 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes among adults with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) in routine clinical practice in Russia.
CONDITIONS
Official Title
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older diagnosed with generalized myasthenia gravis positive for acetylcholine receptor antibodies
- Signed and dated written informed consent provided
You will not qualify if you...
- Currently enrolled in clinical studies for treatment of generalized myasthenia gravis
- Diagnosed with ocular myasthenia gravis only
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Research Site
Kazan', Russia
Actively Recruiting
2
Research Site
Moscow, Russia
Actively Recruiting
3
Research Site
Novosibirsk, Russia
Actively Recruiting
4
Research Site
Rostov-on-Don, Russia
Actively Recruiting
5
Research Site
Saint Petersburg, Russia
Not Yet Recruiting
6
Research Site
Samara, Russia
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here